We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Culture-Free Platform Rapidly Identifies Blood Stream Infections

By LabMedica International staff writers
Posted on 15 Jan 2025

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. More...

Due to their immature immune systems, newborns are especially vulnerable to infections. It is estimated that 2.5 million neonates or infants in the first month of life die annually from sepsis, with the greatest impact in low- and middle-income countries. Since neonatal sepsis progresses quickly, it requires immediate treatment with intravenous fluids and antibiotics. The risk of death from neonatal sepsis increases by 7.6% for every hour that treatment is delayed. Now, a new diagnostic that combines molecular and microfluidic technologies is being developed to rapidly detect pathogens and drug resistance directly from blood in just a few hours.

Melio (Santa Clara, CA, USA) is creating a culture-free platform to identify bloodstream infections, including neonatal sepsis. By integrating advanced molecular and microfluidic technologies, Melio’s diagnostic aims to accurately detect and identify clinically significant pathogens and resistance markers directly from blood in under three hours, a significant improvement over the current standard of care, which requires culture and takes several days. If successful, the diagnostic's ability to test small blood volumes with high negative predictive value would address a critical gap in neonatal sepsis care. It would empower healthcare providers to make timely, targeted antimicrobial decisions—potentially saving lives, reducing unnecessary antibiotic use, and preventing adverse events or hospitalization during a crucial early stage of life. Melio has been awarded USD 3.5 million by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X, Boston, MA, USA) to develop and execute a technical feasibility plan for its culture-free platform.

“Pathogen identification tests today compromise on either the sensitivity or breadth of pathogens detected. It takes a truly disruptive approach to break this tradeoff and deliver on the ‘holy grail’ for bloodstream infections,” said Mridu Sunha, PhD, Founder and CEO of Melio. “Melio has been working tirelessly to re-examine these technical challenges with out-of-the-box thinking, engineering innovative ways to interrogate and identify pathogens that deliver comprehensive testing for known pathogens while enabling detection of emerging or novel threats. We are excited to join the CARB-X ecosystem, which connects us with a network of clinical experts and policy leaders, fostering collaboration, shared learning, and significantly accelerating our path to commercialization.”

“Melio’s technology that utilizes direct from blood isolation using acoustic technology followed by melt curve identification, if successful, would represent a great stride made to detect neonatal sepsis, a syndrome that increases the likelihood of mortality the longer treatment is delayed,” said Erin Duffy, PhD, R&D Chief of CARB-X. “We look forward to working with Melio to understand their technology better and accelerate this diagnostic so that it may reach medical staff and patients more quickly.”

Related Links:
Melio
CARB-X


New
Gold Member
Hematology Analyzer
Medonic M32B
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.